Decision Time For MSD/AZ, Lilly, Kite EU Fast-Track Hopes
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.
You may also be interested in...
Keeping Track Of User Fee Decisions And Filings: Adakveo, Brukinsa And Fetroja Mark Massive Week Of Novel Approvals
The latest news on US FDA user fee decisions and submissions to the agency.
The company reported positive Phase III response rate data weeks after strong results in lung cancer for the RET inhibitor also known as LOXO-292. An NDA submission is on track for later this year.